psychologySpecial Scenario

GLP-1s with Antidepressants

There's no major direct interaction between GLP-1s and SSRIs or SNRIs. But the side effects overlap in ways that matter, and the mood signal flagged on the GLP-1 label deserves attention in this group.

The short answer

GLP-1s and selective serotonin reuptake inhibitors (SSRIs like sertraline, escitalopram, fluoxetine) or serotonin-norepinephrine reuptake inhibitors (SNRIs like venlafaxine, duloxetine) do not have a significant pharmacokinetic interaction. They are safe to take together, and millions of people do. The reasons to pay attention are mostly clinical: overlapping gastrointestinal side effects, a small mood signal that regulators have investigated on the GLP-1 label, and the fact that weight loss itself can shift how you feel and how your antidepressant works.

What to know

There is no metabolic interaction worth memorizing. GLP-1s are large peptide drugs broken down by general protein degradation; they do not go through the cytochrome P450 system that handles most antidepressants. SSRIs and SNRIs are metabolized by CYP2D6, CYP3A4, and CYP1A2. The two systems do not collide, and standard drug interaction checkers consistently classify GLP-1 + SSRI/SNRI as "no significant interaction."

Overlapping side effects are the real friction. Both classes can cause nausea, especially during initiation. SSRIs are notorious for first-week nausea that usually resolves; GLP-1s cause nausea that lasts longer and recurs at each dose escalation. Starting both at the same time is generally avoided — most clinicians will get one stable before adding the other. If you are already stable on an SSRI and start a GLP-1, the SSRI nausea has likely long since resolved and the GLP-1 nausea is the new variable.

Serotonin syndrome is theoretically possible but rare. The mechanism would require something else also raising serotonin (a triptan for migraines, tramadol, MDMA, St. John's wort, another serotonergic drug). GLP-1s themselves are not direct serotonergic agents and have not been implicated in serotonin syndrome in case reports. The practical risk in a person on a stable SSRI dose plus a GLP-1 is essentially zero, but the screen for other serotonergic agents is still worth doing.

The mood signal on the GLP-1 label has been investigated. After post-marketing reports of suicidal ideation in GLP-1 users surfaced in 2023, the European Medicines Agency and FDA both conducted reviews. The EMA review (April 2024) concluded that the available evidence did not establish a causal link between GLP-1s and suicidal thoughts or self-harm. The label still includes a recommendation to monitor for depression or suicidal ideation. People on antidepressants are in this group by definition, and structured monitoring during initiation makes sense.

Weight loss itself changes how mood medications feel. Some patients report mood improvement on a GLP-1 — likely a mix of metabolic, cognitive, and self-image effects. Others report new flatness or anhedonia, which may or may not be the drug. Substantial weight loss can also change the pharmacokinetics of some antidepressants, especially the more lipophilic ones, but dose adjustments based on weight change are uncommon in practice unless symptoms shift.

Practical steps

If you're on both

schedule

Stagger the start, if possible

Get one drug stable before starting the other. If you're already on an SSRI, the GLP-1 is the new variable; if you're already on a GLP-1, give a new SSRI a few weeks before titrating up.

mood

Track mood weekly, not vaguely

A simple 1-10 rating in a notes app, once a week, gives you and your prescriber real data. A drift downward is much easier to catch than a sudden crash.

groups

Make sure both prescribers know

Your psychiatrist or primary care prescriber for the SSRI should know about the GLP-1, and vice versa. This is true for any combo, but especially when one prescriber may not be obesity-trained.

Common questions

Common Concerns

Can I take Zoloft and Wegovy together?expand_more

Yes. Sertraline (Zoloft) and semaglutide (Wegovy) have no significant pharmacokinetic interaction. They are commonly co-prescribed. The practical considerations are overlapping nausea during initiation and the general recommendation to monitor mood on the GLP-1 label.

Will my antidepressant absorb properly if a GLP-1 slows my gut?expand_more

Oral antidepressants are absorbed across the small intestine over hours, and small changes in gastric emptying rate generally do not meaningfully change steady-state blood levels for SSRIs or SNRIs. This is in contrast to oral hormonal contraceptives, where the data did support a real concern with tirzepatide.

Do GLP-1s cause depression?expand_more

Post-marketing reports of suicidal ideation prompted regulatory reviews on both sides of the Atlantic. The European Medicines Agency review in April 2024 did not establish a causal link. The label still recommends monitoring for depression or suicidal thoughts, especially in those with a pre-existing history. People on antidepressants are by definition in that monitoring group.

What about bupropion (Wellbutrin)?expand_more

Bupropion is not an SSRI/SNRI and is also commonly used for weight loss in combination with naltrexone (Contrave). It does not have a known interaction with GLP-1s. Some patients take both — usually under one prescriber's coordination — without obvious additive side effects beyond initial appetite suppression that may overlap.

Can I stop my antidepressant once I lose weight?expand_more

Sometimes, but not on your own. SSRI/SNRI discontinuation should be tapered with the prescribing clinician, and the right time is usually after psychiatric stability is established, not just at a weight milestone. Rapid weight loss is a high-stress period — not the moment to also stop a mood-stabilizing medication.

Keep exploring

Browse all GLP-1 guides.